التفاصيل البيبلوغرافية
| العنوان: |
Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases. |
| المؤلفون: |
Han, Bo1 (AUTHOR), Wang, Mengfei1 (AUTHOR), Li, Jiayi1,2 (AUTHOR), Chen, Qiushi1,2 (AUTHOR), Sun, Niubing1,2 (AUTHOR), Yang, Xuezhi3 (AUTHOR), Zhang, Qingwei1 (AUTHOR) sipiqingwei@163.com |
| المصدر: |
European Journal of Medicinal Chemistry. Oct2023, Vol. 258, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*HISTONE deacetylase inhibitors, *HUNTINGTON disease, *ALZHEIMER'S disease, *BRAIN diseases, *PARKINSON'S disease, *BLOOD-brain barrier |
| مستخلص: |
Many populations worldwide are suffering from central nervous system (CNS) diseases such as brain tumors, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease and Huntington's disease) and stroke. There is a shortage of effective drugs for most CNS diseases. As one of the regulatory mechanisms of epigenetics, the particular role and therapeutic benefits of histone deacetylases (HDACs) in the CNS have been extensively studied. In recent years, HDACs have attracted increasing attention as potential drug targets for CNS diseases. In this review, we summarize the recent applications of representative histone deacetylases inhibitors (HDACis) in CNS diseases and discuss the challenges in developing HDACis with different structures and better blood-brain barrier (BBB) permeability, hoping to promote the development of more effective bioactive HDACis for the treatment of CNS diseases. [Display omitted] • HDACis have received considerable attention as potential therapeutics for various CNS diseases. • Designing HDACis with different structures and better BBB permeability is of great significance but also challenging. • More research is needed on the correlation between specific subtypes of HDACs and CNS diseases. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
